Point-of-care molecular testing has matured from a novelty into a definable portfolio category: sample-to-answer platforms with enclosed workflows that put nucleic-acid results within reach of emergency departments, peripheral clinics, and screening programmes run outside laboratory walls. Portfolio owners now face a refresh question — which near-patient platforms to keep, add, or retire, and how the category should relate to the central laboratory. Refreshed without a framework, the portfolio accretes: single-purpose devices bought for one initiative, overlapping menus, and quality obligations nobody owns.
Where near-patient molecular earns its place
The use cases that justify molecular POCT share a common shape: the result changes a decision within the visit, and the delay of transport to a central laboratory would waste that window. Emergency department respiratory triage where isolation and cohorting decisions are made hourly; tuberculosis and sexually transmitted infection programmes delivered in peripheral clinics without laboratory infrastructure; screening initiatives whose yield depends on same-visit treatment — these are the load-bearing scenarios. Where the result feeds a routine pathway that tolerates a day’s turnaround, the central laboratory remains the better engine on cost, quality oversight, and menu depth. The refresh should begin by mapping every current and proposed site against that test, honestly.
Quality discipline outside the laboratory
A molecular result produced outside a laboratory is held to the same standard as one produced inside it, with none of the environmental control. The refresh must therefore budget for the quality infrastructure: external quality assessment enrolment for every testing site, defined internal QC cadence per platform, operator competency programmes with documented requalification, and connectivity that transmits results, QC status, and reagent lot identity to a supervising laboratory in near-real time. Enclosed cartridges simplify the chemistry but do not remove obligations around ambient temperature limits, shelf-life management in settings without monitored storage, and error-rate monitoring across a fleet of devices. Regulators in most markets have converged on near-patient categories that demand exactly this supervisory model — treat the connectivity and oversight layer as part of the product, not as an optional extra.
A refresh framework
- Map every testing site to its decision window: same-visit action justifies near-patient placement; routine pathways route to the central laboratory
- Consolidate the menu: retire single-purpose devices whose targets are covered by a broader platform already in the fleet, and count training hours released
- Score candidate platforms on workflow simplicity, connectivity, and service model — not only on menu breadth
- Rationalise procurement: common cartridge inventory across sites turns consumable logistics from a per-site problem into a portfolio one
- Define the supervisory laboratory’s oversight scope in writing, including QC review cadence and corrective-action authority
Complement, not compete with, the central laboratory
The refresh succeeds when the near-patient tier and the central laboratory are designed as one system. Confirmatory and reflex pathways — near-patient screen, laboratory confirm — should be defined in the standard operating procedures of both tiers, with methods harmonised so that results are comparable across sites. Fleets report into one quality dashboard, one competency register, and one supply plan. Managed that way, the point-of-care portfolio extends the laboratory’s reach without duplicating its costs, and each tier does the work it is structurally better at.